AI Terminal
Kuros Biosciences Ltd.
Pre-Annual General Meeting Information • Dec 15, 2015
916_rns_2015-12-15_509270a4-d66d-4c12-8d01-3f68f78432fe.html
Pre-Annual General Meeting Information
Open in ViewerOpens in native device viewer
News Details
Ad-hoc | 15 December 2015 07:00
Cytos Biotechnology Ltd. invites for an Extraordinary Shareholders’ Meeting
EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): AGM/EGM
2015-12-15 / 07:00
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.
Cytos Biotechnology Ltd. invites for an Extraordinary Shareholders’ Meeting
Schlieren (Zurich), Switzerland, December 15, 2015 – Cytos Biotechnology Ltd (“Cytos” or “the Company”), announced today that an Extraordinary Shareholders’ Meeting will take place on Wednesday, January 6, 2016 at 10.30 a.m. at Cytos’ offices in Schlieren/Zurich (Switzerland).
At this meeting, shareholders will be invited to vote on resolutions related to the transaction with Kuros Biosurgery Holding AG (acquisition of this company by means of share exchange). Resolutions include an increase of the share capital, amendment of the conditional and authorized capital and elections to the Board of Directors.
The formal invitation to the meeting will be sent out within the next few days and can also be downloaded on the following website:
http://www.cytos.com/uploads/2016/Cytos_invitation_EGM_Jan6_english.pdf
For further information, please contact:
Cytos Biotechnology Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46
About Cytos Biotechnology Ltd
Cytos is a public biopharmaceutical company located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.
Forward Looking Statements
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.
End of ad hoc announcement
+++++
Additional features:
Document: http://n.equitystory.com/c/fncls.ssp?u=PDMWHIYFRK
Document title: Cytos_EGM_151215
2015-12-15 News transmitted by EQS Schweiz AG. www.eqs.com – news archive: http://switzerland.eqs.com/de/News
The issuer is responsible for the contents of the release.
| Language: | English |
| Company: | Cytos Biotechnology AG |
| Wagistr. 25 | |
| 8952 Schlieren | |
| Switzerland | |
| Phone: | +41 44 733 4747 |
| Fax: | +41 44 733 4740 |
| E-mail: | [email protected] |
| Internet: | www.cytos.com |
| ISIN: | CH0011025217, CH0029060735 |
| Valor: | – |
| Listed: | Regulated Unofficial Market in Berlin, Munich, Stuttgart; Open Market in Frankfurt ; SIX |
| End of News | EQS Group News Service |